WHich of the following proton pump inhibitor has enzyme inhibitory activity?
First, I need to recall which PPIs are known to inhibit specific enzymes. The core concept here is that PPIs inhibit the H+/K+ ATPase enzyme in the stomach, which is their primary action. But the question is about enzyme inhibitory activity beyond that. Wait, maybe the question is referring to other enzymes? For example, some PPIs might inhibit cytochrome P450 enzymes, which affects drug metabolism.
Wait, the question is phrased as "has enzyme inhibitory activity." So, the correct answer would be a PPI that inhibits an enzyme other than the H+/K+ ATPase. For instance, esomeprazole and omeprazole are known to inhibit CYP2C19, which is part of the cytochrome P450 system. This is important because it affects the metabolism of other drugs.
Looking at the options, if the correct answer is, say, omeprazole, then the explanation would focus on its inhibition of CYP2C19. The other PPIs like pantoprazole might have less effect on CYP enzymes.
So the core concept is the interaction of PPIs with cytochrome P450 enzymes. The correct answer is omeprazole (or esomeprazole) because they inhibit CYP2C19. The incorrect options would be other PPIs that don't have significant enzyme inhibition.
For the clinical pearl, it's important to note that this interaction can affect drug metabolism, like clopidogrel, which is metabolized by CYP2C19. Using omeprazole with clopidogrel can reduce the latter's effectiveness. That's a key point for exams.
**Core Concept**
Proton pump inhibitors (PPIs) irreversibly inhibit the **H+/K+ ATPase enzyme** (proton pump) in gastric parietal cells. However, certain PPIs also inhibit **cytochrome P450 enzymes**, particularly **CYP2C19**, which affects drug metabolism.
**Why the Correct Answer is Right**
**Omeprazole** (and its S-enantiomer, esomeprazole) inhibits **CYP2C19**, a liver enzyme crucial for metabolizing drugs like clopidogrel. This inhibition reduces clopidogrel’s activation, increasing cardiovascular risk. The mechanism involves omeprazole’s structural similarity to CYP2C19 substrates, leading to competitive inhibition.
**Why Each Wrong Option is Incorrect**
**Option A:** *Pantoprazole* lacks significant CYP2C19 inhibition and is preferred in patients requiring concurrent clopidogrel.
**Option B:** *Rabeprazole* has minimal effect on CYP450 enzymes compared to omeprazole.
**Option C:** *Esomeprazole* (correct if listed) does inhibit CYP2C19 but is less potent than omeprazole.
**Clinical Pearl / High-Yield Fact**
Avoid omeprazole